Proteostasis unbalance of nucleophosmin 1 in Acute Myeloid Leukemia: An aggregomic perspective.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
01 Dec 2020
Historique:
received: 18 05 2020
revised: 31 08 2020
accepted: 31 08 2020
pubmed: 6 9 2020
medline: 13 4 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

The role exerted by the nucleus in the regulation of proteostasis in both health and disease is recognized of outmost importance, even though not fully understood. Many recent investigations are focused on its ability to modulate and coordinate protein quality control machineries in mammalian cells. Nucleophosmin 1 (NPM1) is one of the most abundant nucleolar proteins and its gene is mutated in ~30% of Acute Myeloid Leukemia (AML) patients. Mutations are localized in the C-terminal domain of the protein and cause cytoplasmatically delocalized and possibly aggregated forms of NPM1 (NPM1c+). Therapeutic interventions targeted on NPM1c+ are in demand and, to this end, deeper knowledge of NPM1c+ behavior in the blasts' cytosol is required. Here by means of complementary biophysical techniques we compared the conformational and aggregative behavior of the entire C-terminal domains of NPM1wt and type A NPM1c+ (bearing the most common mutation). Overall data show that only Cterm_mutA is able to form amyloid-like assemblies with fibrillar morphology and that the oligomers are toxic in human neuroblastoma SHSY cells. This study adds a novel piece of knowledge to the comprehension of the molecular roles exerted by cytoplasmatic NPM1c+ and suggests the exploitation of the amyloidogenic propensity of NPM1c+ as a new strategy for targeting AML with NPM1 mutations.

Identifiants

pubmed: 32890557
pii: S0141-8130(20)34346-4
doi: 10.1016/j.ijbiomac.2020.08.248
pii:
doi:

Substances chimiques

Amyloid 0
Amyloidogenic Proteins 0
NPM1 protein, human 0
Nuclear Proteins 0
Nucleophosmin 117896-08-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3501-3507

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Concetta Di Natale (C)

Department of Pharmacy, University of Naples "Federico II", 80134, Italy; Center for Advanced Biomaterial for Health Care (CABHC), Istituto Italiano di Tecnologia, Naples, Italy; Interdisciplinary Research Centre on Biomaterials (CRIB), University of Naples Federico II, P.le Tecchio 80, Naples 80125, Italy.

Daniele Florio (D)

Department of Pharmacy, University of Naples "Federico II", 80134, Italy.

Sarah Di Somma (S)

Department of Translational Medical Science, University of Naples Federico II, 80131 Napoli, Italy.

Adele Di Matteo (A)

Institute of Molecular Biology and Pathology, National Research Council of Italy, c/o Department of Biochemical Sciences "A Rossi Fanelli" - Sapienza University of Rome, 00185 Rome, Italy.

Luca Federici (L)

Center of Advanced Studies and Technology (CAST) and Department of Clinical, Oral and Biotechnological Sciences, University of Chieti "G. d'Annunzio", 66100 Chieti, Italy.

Paolo Antonio Netti (PA)

Center for Advanced Biomaterial for Health Care (CABHC), Istituto Italiano di Tecnologia, Naples, Italy; Interdisciplinary Research Centre on Biomaterials (CRIB), University of Naples Federico II, P.le Tecchio 80, Naples 80125, Italy; Department of Chemical Materials and Industrial Production (DICMAPI), University of Naples Federico II, P.le Tecchio 80, Naples 80125, Italy.

Giancarlo Morelli (G)

Department of Pharmacy, University of Naples "Federico II", 80134, Italy.

Anna Maria Malfitano (AM)

Department of Translational Medical Science, University of Naples Federico II, 80131 Napoli, Italy.

Daniela Marasco (D)

Department of Pharmacy, University of Naples "Federico II", 80134, Italy. Electronic address: daniela.marasco@unina.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH